Port Talbot-based chronic wound care business Hybrisan has been acquired by leading wound care manufacturer Eumar Technology in a deal creating a new contract development manufacturing organisation (CDMO) powerhouse in the UK.
Growing challenge of chronic wounds
Chronic hard-to-heal wounds represent a significant and growing challenge for healthcare systems. The global advanced wound care market has experienced high levels of growth in recent years and was valued at over $20 billion in 2025.
The acquisition positions the combined business to develop and commercialise advanced wound care solutions that improve patient outcomes and support more efficient care pathways.
Hybrisan's expertise and flagship product
Founded in 2013, Hybrisan (the trading name of Universal Synergistic Holdings) has built a strong reputation in chronic wound care. Its lead product, WoundSan, is a clinically evidenced wound cleansing technology currently progressing through EU medical device regulation approval and expected to reach the market later this year.
Hybrisan will continue to operate from its headquarters in Port Talbot, with increased investment from its new owners.
Quotes from key executives
Chris Mortimer, chief technology officer (formerly chief executive of Hybrisan), said: “Combining Hybrisan’s development expertise with Eumar’s manufacturing capability, infrastructure and commercial reach will allow us to accelerate innovative wound care solutions to market. The continuation of operations in Port Talbot ensures the specialist skills we have built in South Wales remain central to the group’s future.”
Euan Davidson, chairman of Eumar Technology, said: “This acquisition is central to our long-term strategy to build a leading UK medical device business. We are committed to investing in skilled employment and manufacturing excellence across both Herefordshire and South Wales, with the goal of creating a CDMO recognised internationally for taking innovative products from concept to commercial manufacture entirely within the UK.”
Advisory and deal details
Frank Holmes (partner) and Sean David (executive) of Cardiff-based Gambit Corporate Finance advised Hybrisan’s shareholders on the transaction. Mr David commented: “Hybrisan’s innovative technology deserves to reach the market, which it will do through its partnership with Eumar. This transaction exemplifies the value to corporate acquirers seeking diversification, growth and competitive advantage, whilst commercialising valuable intellectual property.”
The value of the deal has not been disclosed. In 2014 the business secured a six-figure equity investment from the Development Bank of Wales.
